Disease State Pillar

Chronic Obstructive Pulmonary Disease: A Comprehensive Guide for Primary Care

Miranda Manier, BA

What is COPD?

Chronic obstructive pulmonary disease (COPD) is a progressive, preventable condition marked by airflow limitation and respiratory symptoms such as dyspnea, chronic cough, and sputum production.1 COPD is one of the leading causes of death globally and affects an estimated 15 million individuals in the United States, with millions more undiagnosed.2 The airflow obstruction is not fully reversible and is caused by abnormalities in the airways and alveoli, often triggered by long-term exposure to harmful substances. Recognizing and treating COPD, especially early, can lead to important benefits for patients.

Causes and risk factors

The most significant risk factor for COPD is cigarette smoking, which is responsible for up to 75% of cases.3 Other contributors include secondhand smoke, occupational exposures (dusts, chemicals), indoor biomass fuel exposure (e.g., cooking fires), and environmental pollution.4 There is increasing global concern about the rise of COPD due to non-tobacco-related causes. Alpha-1 antitrypsin deficiency is a genetic condition that causes early-onset emphysema and should be considered in younger patients with little or no smoking history.5

Chronic bronchitis vs emphysema 

COPD includes two overlapping subtypes: chronic bronchitis and emphysema. Chronic bronchitis is defined clinically by a productive cough for at least 3 months in 2 consecutive years.6 Emphysema is characterized by alveolar wall destruction and airspace enlargement, resulting in reduced gas exchange.7 Most patients with COPD have features of both conditions.

Identifying COPD in the primary care setting

Early symptoms and common presentations

Patients with COPD often present with exertional dyspnea, chronic cough, and sputum production. Symptoms typically develop in individuals over age 40 and progress slowly, often leading to delays in diagnosis.8 Patients may attribute their symptoms to aging or poor fitness.

When to suspect COPD

COPD should be suspected in patients with a history of smoking or exposure to airborne irritants who report persistent respiratory symptoms, especially dyspnea with exertion.9 A history of recurrent bronchitis or frequent respiratory infections also raises suspicion. Asthma-COPD overlap can complicate diagnosis, but asthma usually presents earlier in life and is more variable.

How is COPD diagnosed? 

Spirometry and clinical assessment

Spirometry is required to confirm a COPD diagnosis. A post-bronchodilator FEV₁/FVC ratio of less than 0.70 indicates airflow limitation.10 Spirometry should be done in all patients with suspected COPD and repeated periodically, especially since other disorders can have similar clinical presentations. While bronchodilator responsiveness may occur, persistent obstruction confirms COPD.11

GOLD classification and ABCD tool

The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2025 guidelines recommend classifying COPD by spirometric grade (1–4) and grouping patients by symptom burden and exacerbation history using the ABE tool:

  • Group A: Low symptoms, low exacerbation risk
  • Group B: High symptoms, low risk
  • Group E: High exacerbation risk, regardless of symptoms12

Symptom scores (COPD Assessment Tool (CAT) greater than or equal to 10 or modified Medical Research Council (mMRC) ≥2) and history of two or more exacerbations or one or more hospitalization in the prior year help stratify patients.12

Treatment overview for COPD

Pharmacologic therapy by stage

Treatment of COPD is based on GOLD grouping:

  • Group A: Any bronchodilator
  • Group B: Long-acting bronchodilator (long-acting muscarinic antagonists [LAMA] or long-acting beta-2 agonists [LABA])
  • Group E: Start on a LAMA or a combination of LAMA and LABA; inhaled corticosteroids (ICS) may be added if the eosinophil count is 300 cells/μL or higher.

Triple therapy (LAMA+LABA+ICS) reduces exacerbations in high-risk patients and may be used if dual therapy fails.13

Inhaler types and combination approaches

Dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and soft-mist inhalers have different device requirements. Selection should be based on the patient’s ability to use the device correctly. Proper inhaler technique is crucial and should be assessed at every visit.14 Combination inhalers improve adherence by simplifying regimens.15

Non-pharmacological management strategies

Pulmonary rehab, exercise, and oxygen

Pulmonary rehabilitation improves dyspnea, exercise tolerance, and quality of life, and is recommended for patients with an mMRC score of 2 or higher or a recent hospitalization.16 Long-term oxygen therapy (LTOT) is indicated for patients with a PaO₂ of 55 mmHg or less, or an SaO₂ of 88% or lower.12

Lifestyle support and vaccinations

Smoking cessation slows disease progression and is the most effective intervention.3 Annual influenza, pneumococcal, COVID-19, and Tdap vaccinations reduce exacerbation risk.12 Nutrition and mental health support also play a role in COPD care. Physicial conditioning such as formal exercise programs, including pulmonary rehabilitation, have also shown benefit (would probably move ahead of Nutrition and mental health given evidence weight).

Managing COPD exacerbations

Recognizing flare-ups 

Exacerbations are defined as acute worsening of respiratory symptoms that require a change in treatment. Common features include increased dyspnea, cough, and sputum production (especially purulence).17 Common triggers include viral or bacterial infections and environmental pollutants.18

Treatment and follow-up plans

Mild-to-moderate exacerbations can often be treated in outpatient settings using:

  • Short-acting bronchodilators (SABA/SAMA), increased in frequency
  • Oral corticosteroids (e.g., prednisone 40 mg daily for 5 days)10
  • Antibiotics when sputum purulence or clinical infection is present19

Follow-up within 1–4 weeks is essential to reassess symptom control, inhaler technique, and medication adherence. Frequent exacerbations (≥2/year or ≥1 hospitalization) warrant escalation to dual or triple therapy.12

Monitoring and long-term follow-up

Inhaler technique and adherence 

Up to 50% of patients use inhalers incorrectly, making regular technique checks vital.14 Adherence should be reviewed routinely, and regimens simplified when possible. Using one type of inhaler across all medications improves consistency.15

Tracking symptoms and progress 

Validated tools like the CAT or mMRC scale should be used to monitor disease burden. Spirometry may be repeated annually or when symptoms change.11 Documenting exacerbations helps guide therapy intensity and GOLD classification updates.12

When to refer or escalate care

Indications for pulmonology referral

Refer patients with COPD who present with:

  • Need for pulmonary rehabilitation (PR): symptomatic patients (eg, CAT ≥10 or mMRC ≥2), those with exercise limitation, or after a recent COPD hospitalization. If local access is limited, consider virtual/tele-rehabilitation options shown to be safe and effective—even for patients on long-term oxygen therapy.
  • Diagnostic uncertainty
  • Rapid disease progression
  • Frequent exacerbations despite optimized therapy
  • Consideration of roflumilast, azithromycin, oxygen, or lung volume reduction procedures21

Pulmonologists can assess for alpha-1 antitrypsin deficiency, help enroll patients in PR (center-based or virtual), and coordinate advanced interventions such as lung transplant evaluations.

Palliative care and end-stage considerations 

Palliative care is appropriate for patients with severe, refractory dyspnea, psychosocial distress, or repeated hospitalizations.20 Opioids may be used to relieve dyspnea. Hospice should be considered for patients with advanced COPD and a life expectancy of 6 months or less.20

Frequently Asked Questions about COPD for primary care

What’s the best inhaler for patients with COPD?
The best inhaler is one the patient can use correctly and consistently. Device type should match the patient’s physical and cognitive abilities.14

Can COPD be reversed?
No. While symptoms and exacerbation risk can be reduced, the structural lung damage is irreversible. Smoking cessation slows progression.3

How often should patients with COPD be seen?

  • Mild COPD: every 6–12 months
  • Moderate to severe: every 3–6 months
  • Post-exacerbation: within 4 weeks9

Can vaping (e-cigarettes) cause or contribute to COPD?
Evidence is evolving. Recent research reports higher odds of COPD among e-cigarette users—even after adjusting for cigarette smoking—particularly for people who vape and smoke (“dual use”).21,22 However, prospective analyses have shown mixed results.23 Given uncertain harms and no proven benefit of e-cigarettes as a first-line cessation aid, advise complete cessation of all tobacco and nicotine products; use FDA-approved pharmacotherapies and behavioral support instead.24 Major public health agencies also caution that e-cigarette aerosols contain substances that can irritate and injure the lungs.25

References

  1. Criner GJ, Sternberg AL, Martinez FJ, et al. Patient and primary care provider factors associated with quality COPD outpatient care. J Nurse Pract. 2019;15(10):745-753. doi:10.1016/j.nurpra.2019.08.016
  2. Pace WD, Brandt E, Carter VA, et al. COPD population in US primary care: data from the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD registry. Ann Fam Med. 2022;20(4):319-327. doi:10.1370/afm.2829
  3. Sethi S, Donohue JF. Effective management of COPD in primary care: challenges and opportunities. Am J Manag Care. Published online November 30, 2018. Accessed July 11, 2025. https://www.ajmc.com/view/effective-management-of-copd-in-primary-care-challenges-and-opportunities 
  4. Zidaru A, Vasilescu F, Nemes R, et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip Respir Med. 2019;14:28. doi:10.1186/s40248-019-0191-6
  5. Mayo Clinic Staff. COPD: Diagnosis and treatment. Mayo Clinic. Published April 15, 2020. Accessed July 11, 2025. https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353685
  6. Harris S, Moore LP. Diagnosis and staging of COPD in the primary care setting. Clinical Advisor. Published February 23, 2022. Accessed July 11, 2025. https://www.clinicaladvisor.com/features/copd-diagnosis-staging-primary-care-setting/
  7. Keller TL, Hwang AC, Ryskina KL, et al. Association of patient and primary care provider factors with outpatient COPD care quality. Chronic Obstr Pulm Dis. 2022;9(1):55-67. doi:10.15326/jcopdf.2021.0232
  8. Jones PW, Brusselle G, Dal Negro RW,et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21(3):329-36. doi:10.4104/pcrj.2012.00065
  9. Fiesinger T. Managing COPD through primary care: 5 questions to ask your doctor. Village Medical. Published March 1, 2024. Accessed July 11, 2025. https://www.villagemedical.com/journey-to-well/managing-copd-through-primary-care
  10. Buelt A, Rupp M. Treatment of chronic obstructive pulmonary disease: Guidelines from the VA/DoD. Am Fam Physician. 2021;104(1):98-99. https://www.aafp.org/pubs/afp/issues/2021/0700/p98.html
  11. Licskai C, Sin DD, Hernandez P, et al. Improving care for COPD: a Canadian Thoracic Society clinical practice guideline. Thorax. 2024;79(8):725-734. doi:10.1136/thorax-2023-221211
  12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2025 GOLD Pocket Guide: Diagnosis and Management of COPD. Published November 15, 2024. Accessed July 11, 2025. https://goldcopd.org/wp-content/uploads/2024/11/Pocket-Guide-2025-v1.0-New-Format-15Nov2024_WMV.pdf
  13. Criner GJ, Han MK, Martinez FJ, et al. The GOLD 2023 report: living document evolving care. NPJ Prim Care Respir Med. 2023;33(1):49. doi:10.1038/s41533-023-00349-4
  14. Chan AHY, Pleasants RA, Dhand R, et al. Digital inhalers for asthma or chronic obstructive pulmonary disease: a scientific perspective. Pulm Ther. 2021;7(2):345-376. doi:10.1007/s41030-021-00167-4
  15. Halpin DMG, Birk R, Brealey N, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res. 2018;4(2):00119-2017. doi:10.1183/23120541.00119-2017
  16. Hurst JR, Skolnik N, Hansen GJ, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. Eur Respir J. 2021;57(3):2003361. doi:10.1183/13993003.00186-2021
  17. Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017;124:6-14. doi:10.1016/j.rmed.2017.01.006
  18. National Heart, Lung, and Blood Institute. COPD. MedlinePlus. Updated March 1, 2023. Accessed July 11, 2025. https://www.ncbi.nlm.nih.gov/books/NBK559280/
  19. Vollenweider DJ, Jarrett H, Steurer-Stey C, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10:CD004403. doi:10.1002/14651858.CD004403.pub3
  20. Bajwah S, Schihler M, Beernaert K, et al. A consensus framework for specialist palliative care for people with COPD. BMC Palliat Care. 2023;22(1):115. doi:10.1186/s12904-023-01219-y
  21. Shabil M, Malvi A, Khatib MN, et al. Association of electronic cigarette use and risk of COPD: a systematic review and meta-analysis. NPJ Prim Care Respir Med. 2025;35(1):31. doi:10.1038/s41533-025-00438-6
  22. Glantz SA, Nguyen N, Oliveira da Silva AL. Population-based disease odds for e-cigarettes and dual use versus cigarettes. NEJM Evid. 2024;3(3):EVIDoa2300229. doi:10.1056/EVIDoa2300229
  23. Cook SF, Hirschtick JL, Fleischer NL, et al. Cigarettes, ENDS use, and chronic obstructive pulmonary disease incidence: a prospective longitudinal study. Am J Prev Med. 2023;65(2):173-181. doi:10.1016/j.amepre.2023.01.038
  24. U.S. Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: final recommendation statement. Published January 19, 2021. Accessed July 11, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
  25. Centers for Disease Control and Prevention. Health effects of vaping. Smoking and Tobacco Use. Updated January 31, 2025. Accessed July 11, 2025. https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html